Core Insights - Agree Realty Corporation (ADC) reported strong investment activity in 2025, deploying approximately $1.55 billion into retail net lease properties across 41 states, including 338 properties net leased to top-tier tenants [1][9] - The company has reinforced its investment-grade tenant base, with about 66.8% of annualized base rent coming from high-credit tenants as of December 31, 2025, enhancing income stability and long-term cash flow [2][9] - ADC's balance sheet strength is notable, with over $2 billion in liquidity, positioning the REIT to capitalize on acquisition and development opportunities in 2026 [4][5] Investment Activity - In 2025, the company acquired 305 retail net lease properties valued at around $1.44 billion at a 7.2% cap rate, with remaining long-lease terms averaging 11.5 years [3] - Approximately 64.9% of annualized base rents acquired came from investment-grade tenants, contributing to resilient earnings in a competitive retail environment [3] Future Outlook - Agree Realty forecasts 2026 investment activity between $1.25 billion and $1.5 billion, supported by its three growth platforms: acquisitions, development, and the Developer Funding Platform (DFP) [5][6] - The company's disciplined approach reflects a focus on high-quality retail tenants and strategic capital allocation, with a strong pipeline and conservative balance sheet providing a solid foundation for continued earnings growth [5][6] Market Performance - Shares of Agree Realty have increased by 1.9% over the past three months, contrasting with the industry's decline of 0.9% [7] - The Zacks Consensus Estimate for its 2025 and 2026 funds from operations (FFO) per share has slightly increased to $4.31 and $4.54, respectively [7]

Core Insights - One of the main reasons rental properties are popular investments among individual investors is the monthly income they generate [1] - Real Estate Investment Trusts (REITs) also provide similar benefits by distributing dividends [1]

Core Insights - Crescent Biopharma has received regulatory clearances for its investigational new drugs CR-001 and CR-003, with plans to initiate multiple clinical trials in 2026 [1][2][3] Group 1: Regulatory Approvals - The U.S. FDA has cleared Crescent's IND for CR-001, a PD-1 x VEGF bispecific antibody [2] - Crescent's partner, Kelun-Biotech, has received IND approval for CR-003 (SKB105) from the NMPA of China [2] Group 2: Clinical Trials - The Phase 1/2 ASCEND global clinical trial for CR-001 is set to begin in the first quarter of 2026, targeting treatment-naïve and previously treated patients with various solid tumors [3] - The ASCEND trial aims to enroll up to 290 participants to assess the clinical profile of CR-001, with proof-of-concept data expected in the first quarter of 2027 [3] Group 3: Product Details - CR-001 (SKB118) is designed to block PD-1 and VEGF, aiming to enhance T cell activity against tumors and reduce blood supply to tumors [5] - CR-003 (SKB105) is an ADC targeting integrin beta-6 (ITGB6) with a topoisomerase 1 inhibitor payload, designed to minimize systemic toxicity [7] Group 4: Strategic Collaboration - Crescent has a strategic collaboration with Kelun-Biotech, granting Crescent exclusive rights to develop and commercialize CR-003 outside Greater China, while Kelun-Biotech has rights for CR-001 in Greater China [4]

Core Viewpoint - ADC Therapeutics SA has granted options to purchase 6,000 common shares to a new employee as an inducement for employment, aiming to motivate and reward high performance [1][2]. Group 1: Grant Details - The grant was approved by the Compensation Committee under the Company's Inducement Plan to encourage significant contributions to the Company's success [2]. - The options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the next three years, fully vesting by the fourth anniversary [3]. Group 2: Company Overview - ADC Therapeutics is a leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients through its portfolio, including ZYNLONTA [4]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [5]. - The company is also developing a next-generation PSMA-targeting ADC with a differentiated payload and novel linker [5]. Group 3: Company Operations - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, focusing on innovation in ADC development from clinical to commercialization [6].

Core Insights - The article addresses a frequently asked question regarding investment opportunities and strategies in the current market environment [1]. Group 1: Analyst Background - Leo Nelissen is an analyst specializing in economic developments related to supply chains, infrastructure, and commodities [2]. - He is a contributing author for iREIT®+HOYA Capital, focusing on providing insightful analysis and actionable investment ideas, particularly in dividend growth opportunities [2]. Group 2: Investment Position - The analyst has disclosed a beneficial long position in shares of AM, UNP, and RTX through various financial instruments [3].

Core Viewpoint - ADC Therapeutics is under investigation for potential securities fraud and unlawful business practices following a press release regarding clinical trial data that may have misrepresented adverse events [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics, focusing on whether the company and its officers engaged in securities fraud [1]. - The investigation is prompted by concerns over the company's recent disclosures and the implications for investors [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [2]. - The press release, while positive, noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial data, ADC's stock price fell by $0.65 per share, representing a 14.13% decline, closing at $3.95 per share on December 3, 2025 [3].

Core Viewpoint - The article emphasizes the importance of the price at which quality companies are purchased, suggesting that this is a critical factor in successful investing [1]. Group 1 - The author identifies as a buy-and-hold investor focused on quality blue-chip stocks, Business Development Companies (BDCs), and Real Estate Investment Trusts (REITs) [1]. - The goal is to help lower and middle-class workers build investment portfolios consisting of high-quality, dividend-paying companies [1]. - The author aims to provide a new perspective to assist investors in achieving financial independence [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

Core Viewpoint - Agree Realty Corporation (NYSE:ADC) is recognized as one of the highest paying monthly dividend stocks, reflecting its strong dividend performance and stability in the retail real estate sector [1]. Group 1: Company Overview - Agree Realty Corporation is a net-lease REIT that owns free-standing retail properties, including grocery stores, home improvement chains, dollar stores, and pharmacies, which remain popular even during economic downturns [3]. - The company has transitioned from quarterly to monthly dividend payments since 2021, which may appear as a cut but has resulted in consistent annual payout increases since the 2008-09 financial crisis [4]. Group 2: Dividend Performance - Over the past decade, the dividend has grown at an annual rate of 5.3%, with two increases in 2025 already pushing the payout 3.6% higher [5]. - On December 11, the company declared a monthly dividend of $0.262 per share, indicating ongoing commitment to returning value to shareholders [5]. Group 3: Future Outlook - Agree Realty Corporation plans to invest up to $1.65 billion in new properties in 2025, suggesting a focus on growth and expansion in its portfolio [5].

Core Insights - Reaching retirement age presents both advantages and challenges for individuals relying on the U.S. system [1] Group 1 - The U.S. retirement system is a critical factor influencing financial stability for retirees [1] - Many individuals face uncertainty regarding their financial security upon reaching retirement age [1] - The balance between benefits and potential drawbacks of retirement age is a significant concern for the workforce [1]